Alaunos prices 610,399 shares at $3.36 in registered direct offering

Alaunos Therapeutics (TCRT) entered into a definitive agreement with certain investors for the purchase and sale of an aggregate of 610,399 shares of common stock at a purchase price of $3.36 per share in a registered direct offering on June 20, 2025 based on the 5-day average Nasdaq official closing price. The aggregate gross proceeds to the Company of this offering are expected to be approximately $2.0 million, before deducting the offering expenses payable by the Company. The Company currently intends to use the net proceeds of approximately $1.9 million from the offering for its obesity program and general corporate purposes. The transaction is expected to close on or about June 24, 2025, subject to the satisfaction of customary closing conditions.